DESTINY-CRC02 Trial: Trastuzumab Deruxtecan for the Management of mCRC

Opinion
Video

Daniel Ahn, DO, and Tanios Bekaii-Saab, MD, detail the findings of the DESTINY-CRC02 trial, which examined the efficacy of trastuzumab deruxtecan at different dosing levels in breast cancer and gastric cancer patients.

Related Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content